Wave Life Sciences Ltd

For the period ended Dec 31, 2024. Filed Mar 4, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 4, 2025

WVE$3.48+3.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share amounts)

	December 31, 2024	December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$302,078	$200,351
Accounts receivable	1,422	21,086
Prepaid expenses	9,544	9,912
Other current assets	7,350	4,024
Total current assets	320,394	235,373
Long-term assets:
Property and equipment, net of accumulated depreciation of $46,329 and $42,709 as of December 31, 2024 and 2023, respectively	10,128	13,084
Operating lease right-of-use assets	17,870	22,637
Restricted cash	3,760	3,699
Other assets	55	156
Total long-term assets	31,813	39,576
Total assets	$352,207	$274,949
Liabilities, Series A preferred shares and shareholders’ equity
Current liabilities:
Accounts payable	$16,262	$12,839
Accrued expenses and other current liabilities	21,081	16,828
Current portion of deferred revenue	65,972	150,059
Current portion of operating lease liability	7,638	6,714
Total current liabilities	110,953	186,440
Long-term liabilities:
Deferred revenue, net of current portion	6,099	15,601
Operating lease liability, net of current portion	17,766	25,404
Total long-term liabilities	23,865	41,005
Total liabilities	$134,818	$227,445
Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at December 31, 2024 and 2023	$7,874	$7,874
Shareholders’ equity:
Ordinary shares, no par value; 153,037,286 and 119,162,234 shares issued and outstanding at December 31, 2024 and 2023, respectively	$1,175,181	$935,367
Additional paid-in capital	156,454	129,237
Accumulated other comprehensive loss	(262)	(124)
Accumulated deficit	(1,121,858)	(1,024,850)
Total shareholders’ equity	209,515	39,630
Total liabilities, Series A preferred shares and shareholders’ equity	$352,207	$274,949

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.